- Sony Biotechnology
- Sony Biotechnology
Sony Biotechnology is closely monitoring the COVID-19 situation across the globe. Our first priority is to ensure the health and safety of our employees in affected areas around the world. We are reviewing guidance from the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), government agencies, and health officials in a variety of affected countries.
In their quest for answers, Dr. Moshe Sade-Feldman’s team at the Translational Cancer Immunology (TCI) laboratory at Massachusetts General Hospital (MGH), analyzes real-life data from patients treated with immunotherapies. Learn how the team used single-cell profiling to probe the role played by immune cells in patient tumors in the development of the response to cancer therapy.
Discover how flow cytometry, single cell RNA sequencing, and multispectral imaging can be used together to identify key biomarkers in lung cancer immune response.
Learn about a programmable polymer system used to develop the Kiravia Dyes that delivers increased brightness and stability.
Understand sample requirements and basic optimization steps for single-cell assays.
Learn how to set up sorting applications in the areas of cell biology, immunology, and microbiology.
Get to know the software and hardware of the new ID7000 spectral analyzer, including software workflows from startup to shutdown.
Dr. Chris Emig, Founder and Chief Executive of Augmenta Bioworks The B-cell receptor repertoire can now be queried by next generation sequencing (NGS) at a scale that enables the rapid collection of millions of antibody sequences from any given individual. The resulting pool of rationally selected antibodies gives researchers access to a comprehensive database of antigen-specific binders and increases the chances of identifying the best antibody sequences. The growing volume of such NGS antibody repositories opens opportunities for alternative methods of therapeutic antibody discovery. Augmenta Bioworks, a biotechnology company headed by Chris Emig, PhD, Co-Founder and Chief Executive Officer, is actively engaged in the discovery of new therapeutics by harnessing the most powerful force in the fight against disease—natural human immunity. This group has developed a novel strategy called the DeepGrid™ platform, which combines single-cell sorting with RNA sequencing to pinpoint the protective immune response of individuals and translate these discoveries into therapies. Dr. Emig explains, "We’re currently working on immune profiling and antibody discovery. Augmenta provides deep insights into human immune repertoires and a technical suite for discovering antibodies of high therapeutic potential. We work with a range of scientists, from academics seeking better insights into human immunity...
Learn how cell sorting can be integrated into workflows for multiomic analysis of double emulsion microdroplets.
Learn about the approaches used by two scientific groups who have accelerated antibody discovery with these pipeline technologies.